How to Use ASHP^® Injectable Drug Information™

• What Is ASHP^® Injectable Drug Information™ ?

The ASHP^® Injectable Drug Information™ is a collection of summaries of information from the published literature on the pharmaceutics of parenteral medications as applied to the clinical setting. ASHP^® Injectable Drug Information™ is constructed from information derived from 3603 references with the information presented in the standardized structure described below. The purpose of this reference text is to facilitate the use of this clinical pharmaceutics research by knowledgeable health care professionals for the benefit of patients. The summary information from published research is supplemented with information from the labeling of each product and from other references.

The information base summarized in ASHP^® Injectable Drug Information™ is large and highly complex, requiring thoughtful consideration for proper use. This reference text is not, nor should it be considered, elementary in nature or a primer. A single quick glance in a table is not adequate for proper interpretation of this highly complex information base. Proper interpretation includes the obvious need to consider and evaluate all relevant research information and results. Additionally, information on the formulation components (e.g., excipients), product attributes (especially pH), and the known stability behaviors of each parenteral drug, as well as the clinical situation of the patient, must be included in a thoughtful, reasoned evaluation of clinical pharmaceutics questions. Stability and sterility both must be considered in the assignment of beyond-use dates.

• Who Should Use ASHP^® Injectable Drug Information™?

ASHP^® Injectable Drug Information™ is designed for use as a professional reference and guide to the literature on the clinical pharmaceutics of parenteral medications. The intended audience consists of knowledgeable healthcare professionals, particularly pharmacists, who are well versed in the formulation and clinical use of parenteral medications and who have the highly specialized knowledge base, training, and skill set necessary to interpret and apply the information. Practitioners who are not well versed in the formulation, essential properties, and clinical application of parenteral drugs should seek the assistance of more knowledgeable and experienced healthcare professionals to ensure patient safety.

Users of ASHP^® Injectable Drug Information™ must recognize that no reference work, including this one, can substitute for adequate decision-making by healthcare professionals. Proper clinical decisions must be made after considering all aspects of the patient’s condition and needs, with particular attention to the special demands imposed by parenteral medications. ASHP^® Injectable Drug Information™ cannot make decisions for its users. However, in knowledgeable hands, it is a valuable tool for the proper use of parenteral medications.

• Organization of ASHP^® Injectable Drug Information™

ASHP^® Injectable Drug Information™ has been organized as a collection of monographs on each of the drugs. The monographs are arranged alphabetically by nonproprietary (generic) name. The nonproprietary names of the drugs are the United States Adopted Names (USAN) and other official names for drugs as described in the USP Dictionary of USAN and International Drug Names. Also included are some of the trade (proprietary, brand) names and manufacturers of the drug products; this listing is not necessarily comprehensive and should not be considered an endorsement of any product or manufacturer.

All of the information included in ASHP^® Injectable Drug Information™ is referenced so that those who wish to study the original sources may find them. Efforts are ongoing to provide increased specificity of references to product labeling as individually cited references to the labeling for a drug product, including the proprietary name (if available), manufacturer, and revision date of the prescribing information; this will facilitate location of specific labeling that has been used as a reference. In addition, the full list of the AHFS^® Pharmacologic-Therapeutic Classification^© system and specific classification numbers within each individual monograph have been included to facilitate the location of therapeutic information on the drugs.

The monographs have been divided into the subheadings described below:

Products—lists many of the sizes, strengths, volumes, and forms in which the drug is supplied, along with other components of the formulation. Instructions for reconstitution (when applicable) are included in this section.

The products described do not necessarily comprise a comprehensive list of all available products. Rather, some common representative products are described. Furthermore, dosage forms, sizes, and container configurations of parenteral products may undergo important changes during the lifespan of this edition of ASHP^® Injectable Drug Information™.

Following the product descriptions, the pH of the drug products, the osmotic value(s) of the drug and/or dilutions (when available), and other product information such as the sodium content and definition of units are presented.

Practitioners have not always recognized the value and importance of incorporating product formulation information into the thought process that leads to their decision on handling drug compatibility and stability questions. Excipients used in the formulation of commercially available products may vary among manufacturers and can influence drug compatibility and stability; specific product labeling should be consulted for additional formulation details. Consideration of the product information and formulation components, as well as the properties and attributes of the products (especially pH), is essential to proper interpretation of the information presented in ASHP^® Injectable Drug Information™.

Administration—includes route(s) by which the drug can be given, rates of administration (when applicable), and other related administration details.

The administration information is a condensation derived principally from product labeling. For complete information, including dosage information sufficient for prescribing, the reader should refer to product labeling and therapeutically comprehensive references, such as the AHFS^® Drug Information^®.

Stability—describes the drug’s stability and storage requirements. The storage condition terminology of The United States Pharmacopeia, 42nd ed., is used in ASHP^® Injectable Drug Information™.

The United States Pharmacopeia defines controlled room temperature as a temperature that encompasses the usual and customary working environment of 20–25°C and that results in a mean kinetic temperature no greater than 25°C.¹⁷ Temperature excursions between 15–30°C that are experienced in pharmacies, hospitals, warehouses, and during shipping are permitted.¹⁷ Transient temperature elevations up to 40°C also are permitted provided that they do not persist beyond 24 hours and that the mean kinetic temperature does not exceed 25°C.¹⁷ In contrast, room (ambient) temperature is defined simply as a temperature prevailing in a working environment.¹⁷

Protection from excessive heat is often required; excessive heat is defined as any temperature above 40°C.¹⁷ Similarly, protection from freezing may be required for products that are subject to loss of strength or potency or to destructive alteration of their characteristics, in addition to the risk of container breakage, upon exposure to freezing temperatures.¹⁷

Some products may require storage at a cool temperature, which is defined as any temperature between 8–15°C, or a cold temperature, which is defined as any temperature not exceeding 8°C.¹⁷ A refrigerator is defined as a cold place in which the temperature is controlled between 2–8°C.¹⁷ A freezer refers to a place in which the temperature is controlled between -25 and -10°C.¹⁷ Some products may have a recommended storage condition below -20°C, and in such cases, the temperature should be controlled to within 10°C of -20°C.¹⁷

In addition to storage requirements, aspects of drug stability related to pH, freezing, and exposure to light are presented in this section. Also presented is information on repackaging of the drugs or their dilutions in container/closure systems other than the original package (e.g., prefilling into syringes or in ambulatory pump reservoirs). Sorption and filtration characteristics of the drugs are provided as well when this information is available. The information is derived principally from the primary published research literature and is supplemented with information from other sources when available.

Compatibility Information—tabulates the compatibility results of the drug about which the monograph is written with infusion solutions and other drugs based on published reports from the primary research as well as the product labeling. The various entries are listed alphabetically by solution or drug name; the information is completely cross-referenced among the monographs.

Four types of tables are utilized to present the available information, depending on the kind of test being reported. The first type is for information on the compatibility of a drug in various infusion solutions and is depicted in Table 1. The second type of table presents information on two or more drugs in intravenous solutions and is shown in Table 2. The third type of table is used for tests of two or more drugs in syringes and is shown in Table 3. The fourth table format is used for reports of simulated or actual injection into Y-sites and manifolds of administration sets and is shown in Table 4.

Many published articles, especially older ones, do not include all of the information necessary to complete the tables. However, the tables have been completed as fully as possible from the original articles; in some cases, editorial staff have supplemented the published information based on direct communication with the authors of the published research.

Table 1. Solution Compatibility

Monograph drug name
Solution	Mfr	Mfr	Conc/L or %	Remarks	Ref	C/I
(1)	(2)	(3)	(4)	(5)	(6)	(7)
Solution in which the test was conducted. Manufacturer of the solution. Manufacturer of the drug about which the monograph is written. Concentration of the drug about which the monograph is written. (See The Listing of Concentration.) Description of the results of the test. Reference to the original source of the information. Designation of the compatibility (C) or incompatibility (I) of the test result according to conventional guidelines.

 

Table 2. Additive Compatibility

Monograph drug name
Drug	Mfr	Conc/L or %	Mfr	Conc/L or %	Test Soln	Remarks	Refs	C/I
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Monograph title for the test drug. Manufacturer of the test drug. Concentration of the test drug. Manufacturer of the drug about which the monograph is written. Concentration of the drug about which the monograph is written. (See The Listing of Concentration.) Infusion solution in which the test was conducted. Description of the results of the test. Reference to the original source of the information. Designation of the compatibility (C) or incompatibility (I) of the test result according to conventional guidelines.

 

Table 3. Drugs in Syringe Compatibility

Monograph drug name
Drug (in syringe)	Mfr	Amt	Mfr	Amt	Remarks	Ref	C/I
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Monograph title for the test drug. Manufacturer of the test drug. Actual amount of the test drug. Manufacturer of the drug about which the monograph is written. Actual amount of the drug about which the monograph is written. Description of the results of the test. Reference to the original source of the information. Designation of the compatibility (C) or incompatibility (I) of the test result according to conventional guidelines.

 

Table 4. Y-Site Injection Compatibility (1:1 Mixture)

Monograph drug name
Drug	Mfr	Conc	Mfr	Conc	Remarks	Ref	C/I
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Monograph title for the test drug Manufacturer of the test drug. Concentration of the test drug prior to mixing at the Y-site. Manufacturer of the drug about which the monograph is written. Concentration of the drug about which the monograph is written prior to mixing at the Y-site. Description of the results of the test. Reference to the original source of the information. Designation of the compatibility (C) or incompatibility (I) of the test result according to conventional guidelines.

Additional Compatibility Information—provides additional information and discussions of compatibility presented largely in narrative form.

Other Information—contains any relevant auxiliary information concerning the drug that does not fall into the previous categories.

• The Listing of Concentration

The concentrations of all admixtures in intravenous solutions in the tables (Table 1 and Table 2) generally have been indicated in terms of concentration per liter (L) to facilitate comparison of the various studies. In some cases, this may result in amounts of the drug that are greater or lesser than those normally administered (as when the recommended dose is tested in 100 mL of vehicle), but the listings do accurately reflect the actual concentrations tested, expressed in standardized terms. Concentration may be expressed as a percentage for certain drugs or solutions (e.g., dextran, hetastarch, mannitol, fat emulsion) to reflect the style commonly used to express concentration for these products.

For studies involving syringes, the amounts actually used are indicated. The volumes are also listed if available.

For studies of actual or simulated Y-site injection of drugs, the concentrations are cited in terms of concentration per mL of each drug solution prior to mixing at the Y-site. Most published research reports have presented the drug concentrations in this manner, and ASHP^® Injectable Drug Information™ follows this convention. For those few published reports that presented the drug concentrations after mixing at the Y-site, the concentrations have been recalculated to be consistent with the more common presentation style to maintain the consistency of presentation in ASHP^® Injectable Drug Information™. Note that the Y-Site Injection Compatibility table is designed with the assumption of a 1:1 mixture of the subject drug and infusion solution or admixture. For citations reporting other than a 1:1 mixture, the actual amounts tested are specifically noted.

• Designating Compatibility or Incompatibility

Each summary of a published research report appearing in the Compatibility Information tables bears a compatibility indicator (C, I, or ?). A report receives a designation of C when the study results indicate that compatibility of the test samples existed under the test conditions. If the study determined an incompatibility existed under the test conditions, then an I designation is assigned for the ASHP^® Injectable Drug Information™ entry for that study result. A designation of ? indicates that the test result does not clearly fit either the compatibility or incompatibility definition. Specific standardized guidelines are used to assign these compatibility designations and are described below. The citation is designated as a report of compatibility when results of the original article indicated one or more of the following criteria were met:

1. Physical or visual compatibility of the combination was reported (no visible or electronically detected indication of particulate formation, haze, precipitation, color change, or gas evolution).
2. Stability of the components for at least 24 hours in an admixture under the specified conditions was reported (decomposition of 10% or less).
3. Stability of the components for the entire test period, although in some cases it was less than 24 hours, was reported (time periods less than 24 hours have been noted).

 

The citation is designated as a report of incompatibility when the results of the original article indicated either or both of the following criteria were met:

1. A physical or visual incompatibility was reported (visible or electronically detected particulate formation, haze, precipitation, color change, or gas evolution).
2. Greater than 10% decomposition of one or more components in 24 hours or less under the specified conditions was reported (time periods of less than 24 hours have been noted in the table).

 

Reports of test results that do not clearly fit into the compatibility or incompatibility definitions cannot be designated as either. These are indicated with a question mark.

Although these criteria have become the conventional definitions of compatibility and incompatibility, the reader should recognize that the criteria may need to be tempered with professional judgment. Inflexible adherence to the compatibility designations should be avoided. Instead, they should be used as aids in the exercising of professional judgment.

Therapeutic incompatibilities or other drug interactions are not within the scope of ASHP^® Injectable Drug Information™ and are therefore not addressed. Therapeutically comprehensive references and the product labeling should be consulted for such information.

• Interpreting Compatibility Information in ASHP^® Injectable Drug Information™

As mentioned above, the body of information summarized in ASHP^® Injectable Drug Information™ is large and complicated. With the possible exception of a report of immediate gross precipitation, it usually takes some degree of thoughtful consideration and judgment to properly evaluate and appropriately act on the research results that are summarized in this book.

Nowhere is the need for judgment more obvious than when apparently contradictory information appears in two or more published reports. The body of literature in drug-drug and drug-solution compatibility is replete with apparently contradictory results. Except for study results that have been documented later to be incorrect, the conflicting information has been included in ASHP^® Injectable Drug Information™ to provide practitioners with all of the information for their consideration. The conflicting information will be readily apparent to the reader because of the content of the Remarks section as well as the C, I, and ? designations following each citation.

Many or most of the apparently conflicting citations may be the result of differing conditions or materials used in the studies. A variety of factors that can influence the compatibility and stability of drugs must be considered in evaluating such conflicting results, and absolute statements are often difficult or impossible to make. Differences in concentrations, buffering systems, preservatives, vehicles, temperatures, and order of mixing all may play a role. By reviewing a variety of reports, the user of ASHP^® Injectable Drug Information™ is better able to exercise professional judgment with regard to compatibility and stability.

The reader must guard against misinterpretation of research results, which may lead to inappropriate assumptions of compatibility and stability. As an example, a finding of precipitate formation two hours after two drugs are mixed does not imply nor should it be interpreted to mean that the combination is compatible until that time point, when a sudden precipitation occurs. Rather, it should be interpreted to mean that precipitation occurred at some point between mixing and the first observation point at two hours. Such a result would lead to a designation of incompatibility in ASHP^® Injectable Drug Information™.

Precipitation reports can be particularly troublesome for practitioners to deal with because of the variability of the time frames in which they may occur. Apart from combinations that repeatedly result in immediate precipitation, the formation of a precipitate can be unpredictable to some degree. Numerous examples of variable precipitation time frames can be found in the literature, including paclitaxel, etoposide, and sulfamethoxazole-trimethoprim (co-trimoxazole) in infusion solutions and calcium and phosphates precipitation in parenteral nutrition mixtures (e.g., TNAs, TPNs). Differing drug concentrations also can play a role in creating variability in results. A good example of this occurs with co-administered vancomycin hydrochloride and beta-lactam antibiotics. Users of the information in ASHP^® Injectable Drug Information™ must always be aware that a marginally incompatible combination might exhibit precipitation earlier or later than that reported in the literature. In many such cases, the precipitation is ultimately going to occur, it is just the timing that is in question. This is of particular importance for precipitate formation because of the potential for serious adverse clinical consequences, including death, that have occurred. Certainly, users of ASHP^® Injectable Drug Information™ information should always keep in mind and anticipate the possibility of precipitation and its clinical ramifications. Furthermore, all injections and infusions should be inspected for particulate matter and discoloration prior to administration. If found, such injections and solutions should be discarded.

In addition, many research reports cite test solutions or concentrations that may not be appropriate for clinical use. An example would be a report of a drug’s stability in unsterile water. Although the ASHP^® Injectable Drug Information™ summary will accurately reflect the test solutions and conditions that existed in a study, it is certainly inappropriate to misinterpret a stability report like this as being an authorization to use the product clinically. In such cases, the researchers may have used the clinically inappropriate diluent to evaluate the drug’s stability for extrapolation to a more suitable vehicle that is similar, or they may not have recognized that the diluent is clinically unsuitable. In either event, it is incumbent on the practitioner in the clinical setting to use professional judgment to apply the information in an appropriate manner and recognize what is not acceptable clinically.

Further, it should be noted that many of the citations designated incompatible are not absolute. While a particular admixture may incur more than 10% decomposition within 24 hours, the combination may be useful for a shorter time period. The concept of “utility time” or the time to 10% decomposition may be useful in these cases. Unfortunately, such information is often not available. Included in the Remarks columns of the tables are the amount of decomposition, the time period involved, and the temperature at which the study was conducted when this information is available.

Users of ASHP^® Injectable Drug Information™ information should always keep in mind that the information contained in this reference text must be used as a tool and a guide to the research that has been conducted and published. It is not a replacement for thoughtfully considered professional judgment. It falls to the practitioner to interpret the information in light of the clinical situation, including the patient’s needs and status. What is certain is that relying solely on the C or I designation without the application of professional judgment is inappropriate.

• Limitations of the Literature

In addition to conflicting information, many of the published articles have provided only partial evaluations, not looking at all aspects of a drug’s stability and compatibility. This is not surprising considering the complexity, difficulty, and costs of conducting such research. There are, in fact, articles that do provide evaluations of both physical stability/compatibility and chemical stability. But some are devoted only to physical issues, while others examine only chemical stability. Although a finding of precipitation, haze, or other physical effects may constitute an incompatibility (unless transient), the lack of such changes does not rule out chemical deterioration. In some cases, drugs initially designated as compatible because of a lack of visual change were later shown to undergo chemical decomposition. Similarly, the determination of chemical stability does not rule out the presence of unacceptable levels of particulates and/or turbidity in the combination. In a classic case, the drugs leucovorin calcium and fluorouracil were determined to be chemically stable for extended periods by stability-indicating HPLC assays in several studies, but years later, repeated episodes of filter clogging led to the discovery of unacceptable quantities of particulates in combinations of these drugs. The reader must always bear in mind these possibilities when only partial information is available.

And, finally, contemporary practitioners have come to expect that the analytical methods used in reports on the chemical stability of drugs will be validated, stability-indicating methods. However, many early studies used methods that were not demonstrated to be stability indicating.

Biological drugs (therapeutic proteins [e.g., enzymes, monoclonal antibodies, immune globulins]) are particularly sensitive to environmental factors and undergo more complex and numerous degradation pathways than classical drugs.^{3207 3208 3212} In addition to physicochemical instability issues similar to those observed with classical drugs (e.g., precipitation, decomposition), such proteins are subject to other stability issues (e.g., protein conformation, biologic activity) that must be considered.^{3207 3208 3209 3212} Therefore, a single analytic method that only assesses protein concentration is insufficient to determine stability of biological products.^3209 3210 Interpretation of the results of compatibility and stability studies of such proteins poses a challenge because both analytic methods and meaningful acceptance criteria should be specific to the biologic; official compendial standards (e.g., The United States Pharmacopeia monographs and analytic methods) should be consulted when available.^{3206 3209 3212} Although many experts agree that multiple complementary methods should be used to assess the physical and chemical stability as well as assessment of biologic activity, no clear guideline or recommendation for in-use stability studies for therapeutic proteins is available.^{3208 3210 3211 3212}

• Literature Search for Updating ASHP^® Injectable Drug Information™

To gather the bulk of the published compatibility and stability information for updating ASHP^® Injectable Drug Information™, a literature search is performed using the International Pharmaceutical Abstracts^™ (IPA^™) database and PubMed. By using key terms (e.g., stability), a listing of candidate articles for inclusion in ASHP^® Injectable Drug Information™ is generated. From this list, relevant articles are critically evaluated and prioritized for inclusion. As a supplement to this automated literature searching, a manual search of the references of the articles is also conducted, and any articles not included previously are similarly evaluated for inclusion. In addition, pharmaceutical manufacturers may be contacted for additional in-house (unpublished) data.

• Abbreviations

AA	Amino acids (percentage specified)
D	Dextrose solution (percentage unspecified)
D5LR	Dextrose 5% in Ringer’s injection, lactated
D5R	Dextrose 5% in Ringer’s injection
D-S	Dextrose-saline combinations
D2.5½S	Dextrose 2.5% in sodium chloride 0.45%
D2.5S	Dextrose 2.5% in sodium chloride 0.9%
D5¼S	Dextrose 5% in sodium chloride 0.225%
D5½S	Dextrose 5% in sodium chloride 0.45%
D5S	Dextrose 5% in sodium chloride 0.9%
D10S	Dextrose 10% in sodium chloride 0.9%
D5W	Dextrose 5%
D10W	Dextrose 10%
IM	Isolyte M
IP	Isolyte P
IS10	Invert sugar 10%
I.U.a	International unit(s)
LR	Ringer’s injection, lactated
NM	Normosol M
NR	Normosol R
NRD5W	Normosol R in dextrose 5%
NS	Sodium chloride 0.9%
R	Ringer’s injections
REF	Refrigeration
RT	Room temperature
S	Saline solution (percentage unspecified)
½S	Sodium chloride 0.45%
SL	Sodium lactate 1/6 M
TNA	Total nutrient admixture (3-in-1)
TPN	Total parenteral nutrition (2-in-1)
W	Sterile water for injection
a It is well accepted that “IU” is not a preferred abbreviation for international units. There is some difference of opinion among medication safety stakeholders on whether such units should be referred to simply as “units” or as “International Units.” Throughout the text of this reference, we generally have used the term international units to describe such units; however, because of space limitations within the columns of the Compatibility Information tables, the term international units has been abbreviated as I.U. where necessary.

• Manufacturer and Compendium Abbreviations

AB	Abbott
ABV	AbbVie
ABX	Abraxis
ACA	Acacia
ACC	American Critical Care
ACD	Accord Healthcare
ACH	Achaogen
ACT	Actavis
AD	Adria
AFT	AFT
AGT	Aguettant
AH	Allen & Hanburys
AHP	Ascot Hospital Pharmaceuticals
AKN	Akorn
ALL	Allergan
ALP	Alpharma
ALT	Altana Pharma
ALV	Alveda Pharma
ALZ	Alza
AM	ASTA Medica
AMA	AMAG
AMB	Amneal Biosciences
AMD	Amdipharm
AMG	Amgen
AMP	Amphastar
AMR	American Regent
AMS	Amerisource
AND	Andromaco
ANT	Antigen
AP	Asta-Pharma
APC	Apothecon
APN	Aspen
APO	Apotex
APP	American Pharmaceutical Partners
APR	Aspri
APT	Aspen Triton
AQ	American Quinine
AR	Armour
ARC	American Red Cross
ARD	Ardeapharm
ARR	Arrow
AS	Arnar-Stone
ASC	Ascot
ASP	Astellas Pharma
AST	Astra
ASZ	AstraZeneca
AT	Alpha Therapeutic
ATX	Athenex
AUB	Aurobindo
AUR	Auromedics
AVD	Avadel Legacy Pharmaceuticals
AVE	Aventis
AVG	Alvogen
AW	Asta Werke
AY	Ayerst
AZV	Laboratórios Azevedos
BA	Baxter
BB	B & B Pharmaceuticals
BAN	Banyu Pharmaceuticals
BAY	Bayer
BC	Bencard
BCT	BioCryst Pharmaceuticals
BD	Becton Dickinson
BE	Beecham
BED	Bedford
BEH	Behring
BEL	R. Bellon
BFM	Bieffe Medital
BI	Boehringer Ingelheim
BIO	Bioniche Pharma
BK	Berk
BKN	Baker Norton
BM	Boehringer Mannheim
BMS	Bristol-Myers Squibb
BN	Breon
BP	British Pharmacopoeiaa
BPC	British Pharmaceutical Codexa
BPI	BPI Labs
BR	Bristol
BRD	Bracco Diagnostics
BRK	Breckenridge
BRN	B. Braun
BRT	Britianna
BT	Boots
BTK	Biotika
BV	Ben Venue
BW	Burroughs Wellcome
BX	Berlex
BXT	Baxalta
CA	Calmic
CAD	Cadence Pharmaceuticals
CAR	Cardinal Health
CBH	CSL Behring
CDM	CDM Lavoisier
CE	Carlo Erba
CEL	Celgene
CEN	Centocor
CER	Cerenex
CET	Cetus
CH	Lab. Choay Societe Anonyme
CHI	Chiron
CHS	Chiesi
CHU	Chugai
CI	Ciba
CIP	Cipla
CIS	CIS US
CL	Clintec
CLA	Claris Lifesciences
CLN	Clinigen
CMB	Cumberland
CMP	CMP Pharma
CN	Connaught
CNF	Centrafarm
CO	Cole
COM	CommScope
COR	COR Therapeutics
COV	Covis
CP	Continental Pharma
CPP	CP Pharmaceuticals
CPR	Cooper
CR	Critikon
CRC	Caraco
CSL	CSL Ltd.
CTI	Cell Therapeutics Inc.
CU	Cutter
CUB	Cubist
CUP	Cura Pharmaceuticals
CUR	Curomed
CY	Cyanamid
DAK	Dakota
DB	David Bull Laboratories
DCC	Dupont Critical Care
DGL	Douglas
DI	Dista
DIA	Diamant
DM	Dome
DME	Dupont Merck Pharma
DMX	Dumex
DRA	Dr. Rentschler Arzneimittel
DRT	Durata Therapeutics
DRX	Draxis
DU	DuPont
DUR	Dura
DW	Delta West
EA	Eaton
EBE	Ebewe
ECL	Éclat
EGL	Eagle
EI	Eisai
ELN	Elan
EN	Endo
ENZ	Enzon
ERF	Erfa
ERM	Erempharma
ES	Elkins-Sinn
ESL	ESI Lederle
ESP	ESP Pharma
EST	Esteve
EV	Evans
EX	Essex
EXL	Exela
FA	Farmitalia
FAC	Facta Farmaceutical
FAN	Fandre Laboratories
FAU	Faulding
FC	Frosst & Cie
FED	Federa
FER	Ferring
FI	Fisons
FOR	Forest Laboratories
FP	Faro Pharma
FRE	Fresenius
FRK	Fresenius Kabi
FUJ	Fujisawa
GEI	Geistich Pharma
GEM	Geneva-Marsam
GEN	Genentech
GG	Geigy
GH	Generic Health
GIL	Gilead
GIU	Giulini
GL	Glaxo
GLT	Generics Limited
GNS	Gensia-Sicor
GO	Goedecke
GRI	Grifols
GRP	Gruppo
GRU	Grunenthal
GSK	GlaxoSmithKline
GVA	Geneva
GW	Glaxo Wellcome
GZ	Genzyme
HAE	Haemonetics
HB	Hoechst-Biotika
HC	Hillcross
HE	Hengrui Medicine Co.
HEL	Helsinn
HER	Heritage
HIK	Hikma
HMR	Hoechst Marion Roussel
HO	Hoechst-Roussel
HOS	Hospira
HQS	HQ Specialty Pharma
HR	Horner
HRN	Heron
HY	Hyland
ICI	ICI Pharmaceuticals
ICN	ICN Pharmaceuticals
IMM	Immunex
IMS	IMS Ltd.
IN	Intra
INT	Intermune
IV	Ives
IVX	Ivex
IX	Invenex
JAZ	Jazz
JC	Janssen-Cilag
JHP	JHP Pharmaceuticals
JJ	Johnson & Johnson
JN	Janssen
JP	Jones Pharma
KA	Kabi
KED	Kedrion
KEY	Key Pharmaceuticals
KN	Knoll
KP	Kabi Pharmacia
KV	Kabi-Vitrum
KY	Kyowa
LA	Lagap
LE	Lederle
LEM	Lemmon
LEO	Leo Laboratories
LFB	Laboratoire Français du Fractionnement et des Biotechnologies
LI	Lilly
LIF	Lifeshield
LJ	La Jolla
LME	Laboratoire Meram
LUN	Lundbeck
LY	Lyphomed
LZ	Labaz Laboratories
MA	Mallinckrodt
MAC	Maco Pharma
MAR	Marsam
MAY	Mayne Pharma
MB	May & Baker
MCD	Merck Chibret Dohme
MDI	Medimmune
MDX	Medex
MDZ	Medicianz
ME	Merck
MEL	Melinta Therapeutics
MER	Merus Labs
MG	McGaw
MGI	MGI Pharma
MI	Miles
MIL	Millimed
MJ	Mead Johnson
MM	Merrimack
MMD	Marion Merrell Dow
MMT	Meridian Medical Technologies
MN	McNeil
MON	Monarch
MRD	Merrell-Dow
MRN	Merrell-National
MSD	Merck Sharp & Dohme
MTN	Marathon
MUN	Mundi Pharma
MY	Maney
MYL	Mylan
MYR	Mayrhofer Pharmazeutika
NA	National
NAB	Nabi
NAP	NAPP Pharmaceuticals
NCI	National Cancer Institute
NE	Norwich-Eaton
NIN	Ningbo Team
NF	National Formularya
NO	Nordic
NOP	Novopharm
NOV	Novo Pharm
NVA	Novartis
NVN	Novo Nordisk
NVP	Nova Plus
NVX	Novex Pharma
NYC	Nycomed
OCT	Octapharma
OHM	Ohmeda
OM	Omega
OMJ	OMJ Pharmaceuticals
OMN	Ortho-McNeil
ON	Orion
OR	Organon
ORC	Orchid
ORP	Orphan Medical
ORT	Ortho
OTS	Otsuka
OVA	Ovation
PAD	Paddock
PAL	Paladin
PAN	Panpharma Laboratory
PAR	Par
PB	Pohl-Boskamp
PD	Parke-Davis
PE	Pentagone
PF	Pfizer
PFM	Pfrimmer
PH	Pharmacia
PHC	Pharmachemie
PHM	Pharmacosmos
PHS	Pharmascience
PHT	Pharma-Tek
PHU	Pharmacia & Upjohn
PHX	Phoenix
PNN	Pantheon
PNT	Parenta
PO	Poulenc
PP	Pharmaceutical Partners
PPC	Pharmaceutical Partners of Canada
PPR	Premier Pro Rx
PR	Pasadena Research
PRF	Pierre Fabre
PRK	Parkfields
PRM	Premier
PRP	Premier Pro
PTK	Paratek
PX	Pharmax
QI	Qilu
QLM	Qualimed Labs
QU	Quad
RB	Robins
RBP	Ribosepharm
RC	Roche
REG	Regeneron
REN	Renaudin
RI	Riker
RKB	Reckitt & Benckhiser
RKC	Reckitt & Colman
ROR	Rorer
ROX	Roxane
RP	Rhone-Poulenc
RPR	Rhone-Poulenc Rorer
RR	Roerig
RS	Roussel
RU	Rugby
SA	Sankyo
SAA	Sanofi Aventis
SAG	Sageant
SAN	Sanofi
SB	Sintetica Bioren
SC	Schering
SCI	Scios
SCN	Schein
SCS	SCS Pharmaceuticals
SE	Searle
SEQ	Sequus
SER	Servier
SGS	SangStat
SGT	Sagent
SHI	Shionogi
SIA	Siam Pharmaceutical
SIC	Sicor
SIG	Sigma Tau
SKB	SmithKline Beecham
SKF	Smith Kline & French
SM	Smith
SMX	SteriMax
SN	Smith + Nephew
SO	SoloPak
SP	Spectrum Pharmaceuticals
SQ	Squibb
SRB	Serb
SS	Sanofi-Synthelabo
ST	Sterilab
STP	Sterop
STR	Sterling
STS	Steris
STU	Stuart
SUN	Sun
SV	Savage
SW	Sanofi Winthrop
SX	Sabex
SY	Syntex
SYN	Synergen
SYO	Synthelabo
SZ	Sandoz
TAK	Takeda
TAL	Talon Therapeutics
TAP	TAP Holdings
TAR	Targanta Therapeutics
TAY	Taylor
TE	Teva
TEC	Teclapharm
TEL	Teligent
TES	Tesaro
TET	Tetraphase
TL	Tillotts
TMC	The Medicines Company
TO	Torigian
TR	Travenol
TRE	Trevena
UCB	UCB
UP	Upjohn
USB	US Bioscience
USP	United States Pharmacopeiaa
USV	USV Pharmaceuticals
UT	United Therapeutics
VHA	VHA Plus
VI	Vitarine
VIC	Vicuron Pharmaceuticals
VT	Vitrum
WAS	Wasserman
WAT	Watson
WAY	Wyeth-Ayerst
WB	Winthrop-Breon
WC	Warner-Chilcott
WED	Weddel
WEL	Wellcome
WI	Winthrop
WG	WG Critical Care
WL	Warner Lambert
WOC	Wockhardt
WW	Westward
WY	Wyeth
XGN	X-Gen
XU	Xudong Pharmaceutical Co.
YAM	Yamanouchi
ZEN	Zeneca
ZLB	ZLB Biopharma
ZNS	Zeneus Pharma
ZY	ZyGenerics
ZYD	Zydus
a While reference to a compendium does not indicate the specific manufacturer of a product, it does help to indicate the formulation that was used in the test.

ASHP® Injectable Drug Information™. © Copyright, 1977-2021. American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Original Publication Date: October 1, 1977. Selected Revisions: December 23, 2020. Database Extraction: 02/10/2021 18:22:15 -0500+

 

References

For a list of references cited in the text of this monograph, search the monograph titled References.

The following tables summarize the composition of the total parenteral nutrition mixtures that are referenced throughout the Handbook on Injectable Drugs. Each unique formula that has been tested for stability and/or compatibility characteristics, alone or in combination with other drugs, is described and assigned a code number. These code numbers are used in the drug monographs to denote the TNA (3-in-1) or TPN (2-in-1) formulation being discussed (i.e., TPN #183, TPN #184, etc.). The TNA and TPN formulations are described as completely as possible from the original published sources.

The consolidation of the formulations into a single appendix is designed to avoid unnecessary repetition and to facilitate comparisons among different mixtures.

^a Potassium salt.

		Concentration per Liter
Component	Mfr	#21	#22	#23	#24
Amino acids	MG	200 mL
Amino acids 8.5% with electrolytes	TR		500 mL	500 mL	500 mL
Dextrose 50%		400 mL		500 mL	500 mL
Dextrose 33.3% in water			500 mL
Phosphate		15 mEqa	30 mEq		30 mEqa
Acetate		15 mEqa	67.5 mEq
Calcium gluconate		2 g	9 mEq	1 g
Calcium chloride			7.2 mEq
Potassium chloride			70 mEq		20 mEq
Sodium chloride		40 mEq	55 mEq		60 mEq
Magnesium sulfate		8.1 mEq
Multivitamins		10 mL
Multivitamin concentrate				5 mL
Water for injection		qs 1000 mL
Trace elements			present

 

 

^a Each 25 mL provides: sodium, 25 mEq; potassium, 40.5 mEq; calcium, 5 mEq; magnesium, 8 mEq; chloride, 33.5 mEq; acetate, 40.6 mEq; and gluconate, 5 mEq.
^b Each 3.5 mL provides: zinc, 2 mg; copper, 1 mg; manganese, 0.5 mg; and chromium, 10 mcg.

		Concentration per Liter
Component	Mfr	#25	#26	#27	#28	#29	#30
Amino acids (Aminosyn)	AB	3.5%			1%
Amino acids (FreAmine III)	MG		4.25%			1%
Amino acids (Travasol)	TR			4.25%			1%
Dextrose		25%	25%	25%	25%	25%	25%
Sodium phosphate	AB	10 mmol	10 mmol	10 mmol	10 mmol	10 mmol	10 mmol
Multivitamins (M.V.I.-12)	USV	10 mL	10 mL	10 mL	10 mL	10 mL	10 mL
Multielectrolyte concentratea	SE	25 mL	25 mL	25 mL	25 mL	25 mL	25 mL
Trace mineral injectionb		3.5 mL	3.5 mL	3.5 mL	3.5 mL	3.5 mL	3.5 mL

 

 

^a Trace elements: selenium, 120 mcg; chromium, 2 mcg; zinc, 3 mg; and manganese, 0.7 mg.
^b Trace elements: iodine, 120 mcg; and copper, 1 mg.

		Concentration per Liter
Component		#31	#32	#33	#34	#35	#36	#37
Amino acids	TR	4.2%	4.2%	4.2%	4.2%	4.2%	4.2%	4.2%
Dextrose		25%	25%	25%	25%	25%	25%	25%
Sodium		29 mEq	29 mEq	29 mEq	29 mEq	69 mEq	69 mEq	69 mEq
Potassium		25 mEq	25 mEq	25 mEq	25 mEq	46 mEq	46 mEq	46 mEq
Calcium		9 mEq	9 mEq	9 mEq	4.5 mEq	9.5 mEq	9.5 mEq	9.5 mEq
Magnesium		4 mEq	4 mEq	4 mEq	4 mEq	12 mEq	12 mEq	12 mEq
Phosphorus		388 mg	388 mg	388 mg	388 mg	388 mg	388 mg	388 mg
Chloride		29 mEq	29 mEq	29 mEq	29 mEq	103 mEq	103 mEq	103 mEq
Acetate		63 mEq	63 mEq	63 mEq	63 mEq	63 mEq	63 mEq	63 mEq
Trace elements			a b	a		a b	a b	a b
Multivitamins	USV			10 mL			5 mL	5 mL
Vitamin B complex with C plus folic acid (Soluzyme)	UP			5 mL				5 mL

 

 

		Concentration per Liter
Component		#48	#49	#50	#51
Amino acids		5%	5%	5%	5%
Dextrose		5%	5%	25%	25%
Vitamins		present		present
Trace elements			present		present

 

^a Adjusted to provide 2.5 mEq/kg/day.
^b Present as the gluconate.
^c Anion not specified.
^d Present as the potassium salt.
^e Adjusted to provide 5 mEq/kg/day.
^f Present but concentration not specified.

		Concentration per Liter
Component	Mfr	#52	#53	#54	#55	#56
Amino acids	VT	7%	2.3%
Amino acids	AB			1.5%
Amino acids (FreAmine III)	MG				3%	3%
Dextrose			6.5%	15%	25%	25%
Fructose		10%	3.2%
Sodium		50 mmol	16.2 mmol	a	35 mEq	35 mEq
Potassium		20 mmol	18.4 mmol	a
Calcium		2.5 mmol	4.9 mmol	300 mg	5 mEqb	5 mEqb
Magnesium		1.5 mmol	2.1 mmol		8 mEq	8 mEq
Phosphorus				155 mg
Phosphate			12.1 mmolc		40 mEqd	40 mEqd
Chloride		55 mmol	17.8 mmol	e	35 mEq	35 mEq
Laevulate calcium			9.8 mmol
Folic acid				0.5 mg
Cyanocobalamin				f
Phytonadione				0.2 mg
Multivitamins			present	4 mL		10 mL
Vitamin B complex with C (Berocca-C)				0.2 mL

 

 

^a Concentration per 1200 mL.

		Concentration per Liter
Component	Mfr	#57	#58a	#59	#60	#61
Amino acids	MG	2.125%	4.25%
Amino acids	TR			2.125%
Amino acids	AB				3%
Amino acids with electrolytes	TR			4.25%
Dextrose		10%	25%	25%	25%	20%
Sodium		40 mEq	100 mmol	50 mEq	50 mEq	30 mEq
Potassium		30 mEq	60 to 80 mmol			25 mEq
Calcium		15 mEq	5 mmol	5 mEq	5 mEq	15 mEq
Magnesium		12.5 mEq	5 mmol	5 mEq	5 mEq	10 mEq
Phosphorus		6 mmol	10 mmol	465 mg	465 mg	15 mmol
Chloride		40 mEq	100 mmol	50 mEq	50 mEq
Heparin sodium			1000 units	500 units	500 units
Phytonadione				1 mg	1 mg
Multivitamins			10 mL	10 mL	10 mL	2 mL
Multivitamin concentrate		2 mL
Iron			1 mg
Trace elements		present	present	present	present	present

 

^a Tested both with and without multivitamins.

		Component Amounts
Component	Mfr	#62	#63	#64	#65	#66	#67	#68
Amino acids 8.5% (FreAmine III)	MG	500 mL	500 mL			500 mL
Amino acids 5.4% (Nephramine)	MG			500 mL			500 mL
Amino acids 5.2% (Aminosyn RF)	AB				500 mL			500 mL
Dextrose 50%	MG	500 mL	500 mL	500 mL	500 mL	500 mL	500 mL	500 mL
Hyperlyte (electrolyte) concentrate	MG		25 mL
Fat emulsion 10%, intravenous	CU					500 mL	500 mL	500 mL
Multivitamins (M.V.I.-12)	USV	a	a	a	a	a	a	a

 

 

^a Each 1500 mL provides: sodium, 105 mEq; potassium, 90 mEq; magnesium, 15 mEq; chloride, 105 mEq; acetate, 203 mEq; and phosphate, 45 mmol.
^b Each 500 mL provides: magnesium, 14 mmol; calcium, 13 mmol; chloride, 54 mmol; acetate, 0.08 mmol; zinc, 0.04 mmol; and manganese, 0.02 mmol.

		Component Amounts
Component	Mfr	#69	#70	#71
Amino acids 8.5% (FreAmine II)	MG	1000 mL
Amino acids 8.5% with electrolytes	TR			1500 mLa
Amino acids 7%	AB		500 mL
Dextrose 50%		500 mL	500 mL	1500 mL
Dextrose 20% with electrolyte pattern A	TR	500 mLb
Dextrose 20%		500 mL
Sodium chloride 0.9%		500 mL
Potassium chloride		20 mmol
Calcium gluconate 10%				30 mL
Multivitamins		1 ampul		10 mL
Multivitamin concentrate			5 mL
Folic acid		1 mg	0.25, 0.5, 0.75, 1 mg
Trace elements				present

 

 

		Component Amounts
Component	Mfr	#72	#73	#74	#75
Amino acids 10%	TR	750 mL	750 mL
Amino acids 8.5%	TR			500 mL
Amino acids 8.5%	MG				500 mL
Dextrose 70%		429 mL	429 mL		300 mL
Dextrose 50%				500 mL
Fat emulsion 20%, intravenous	TR	225 mL	225 mL
Sterile water for injection		24.2 mL	15 mL		300 mL
Calcium gluconate 10%		20 mL	20 mL
Calcium gluceptate					8 mEq
Sodium phosphate			15 mmol
Potassium phosphate		20 mmol		30 mEq	18 mEq
Potassium chloride		30 mEq	40 mEq	20 mEq	20 mEq
Magnesium sulfate 50%		2 mL	2 mL		8 mEq
Sodium chloride		60 mEq	60 mEq	40 mEq	60 mEq
Sodium acetate					5 mEq
Heparin sodium			6000 units
Multivitamins		10 mL	10 mL
Trace elements		present	present

 

^a Insulin 10 to 40 units/L.

		Concentration per Liter
Component	Mfr	#86	#87	#88
Amino acids (Aminosyn)	AB	2.5%	4.25%	5%
Dextrose		10%	25%	35%
Calcium		4.5 mEq	4.5 mEq	4.5 mEq
Magnesium		5 mEq	5 mEq	5 mEq
Potassium		23 mEq	40 mEq	40 mEq
Sodium		47 mEq	35 mEq	35 mEq
Acetate		82 mEq	74.5 mEq	74.5 mEq
Chloride		35 mEq	52.5 mEq	52.5 mEq
Phosphorus		9 mmol	12 mmol	12 mmol
Heparin sodium		1000 units	1000 units	1000 units
Insulin		a	a	a

 

 

		Concentration per Liter
Component		#89	#90
Amino acids (Travasol)		4.25%
Amino acids with electrolytes (Travasol with electrolytes)			4.25%
Dextrose		25%	25%

 

^a Trace elements: zinc, 600 mcg; copper, 40 mcg; manganese, 10 mcg; and chromium, 0.4 mcg.

		Concentration per 100 mL	Concentration per 2 L
Component	Mfr	#91	#92
Amino acids 10%		1.6 mL
Nitrogen (from amino acids)	PFM		14 g
Dextrose 5%		15 mL
Dextrose 50%			500 mL
Fat emulsion 20%, intravenous	KA		500 mL
Sodium		3 mEq	150 mEq
Potassium		2.2 mEq	120 mEq
Calcium		1 mEq	15 mEq
Magnesium		0.3 mEq	30 mEq
Phosphate		0.5 mmol	30 mmol
Chloride		2.5 mEq	150 mEq
Sulfate			30 mEq
Acetate			90 mEq
Pediatric multivitamins		5 mL
Multivitamins			present
Trace elements		a	present
Heparin sodium		100 units
Water for injection			qs 2000 mL

 

 

		Concentration per Liter
Component	Mfr	#93	#94	#95	#96
Amino acids	TR	4.25%	4.25%
Amino acids	AB			3%	3%
Dextrose		25%	25%	20%	20%
Potassium chloride		15 mEq	15 mEq	25 mEq	25 mEq
Sodium chloride		15 mEq	15 mEq	30 mEq	30 mEq
Calcium gluconate		4.7 mEq	4.7 mEq	15 mEq	15 mEq
Magnesium sulfate		4.05 mEq	4.05 mEq	10 mEq	10 mEq
Potassium phosphate		5 mEq	5 mEq	15 mmol	15 mmol
Sodium phosphate		10 mEq	10 mEq
Zinc		1.5 mg	1.5 mg	3 mg	3 mg
Manganese		150 mcg	150 mcg	50 mcg	50 mcg
Chromium		6 mcg	6 mcg	2 mcg	2 mcg
Selenium		30 mcg	30 mcg
Copper			600 mcg	200 mcg	200 mcg
Multivitamins	LY			2 mL	2 mL
Heparin sodium	IX			1000 units

 

^a Each TNA admixture also contained: sodium, 25 mEq; potassium, 25 mEq; calcium, 5 mEq; magnesium, 25 mEq; chloride, 30 mEq; acetate, 7.5 mEq; lactate, 10.5 mEq; phosphate, 1.5 mmol; multivitamins (M.V.I. Pediatric), 2.5 mL; trace elements; and heparin sodium, 250 units.

		Milliliters per Container
Component	Mfr	#97	#98	#99	#100	#101	#102	#103	#104
Amino acids 8.5% (FreAmine III)	MG	10	10	10	10	75	75	75	75
Dextrose 70%		89	36	89	36	89	36	89	36
Fat emulsion 20%, intravenous (Intralipid)	KV	5	5	75	75	5	5	50	50
Sterile water qs ad		250	250	250	250	250	250	250	250
Other components		a	a	a	a	a	a	a	a

 

 

		Concentration per Liter
Component	Mfr	#105	#106	#107	#108
Amino acids	TR	1.65%	4.25%	1.5%	1.5%
Dextrose		10%	10%	15%	15%
Sodium		21 mEq	35 mEq
Potassium		18 mEq	30 mEq
Magnesium		3 mEq	5 mEq
Calcium		15 mEq	10 mEq
Phosphate		10 mmol	15 mmol
Chloride		21 mEq	35 mEq
Acetate		30 mEq	68 mEq
Pediatric multivitamins		1 mL	1 mL
Trace elements		0.1 mL	0.1 mL
Unspecified electrolytes and vitamins				present	present

 

^a Not cited.

		Concentration per Liter
Component	Mfr	#109	#110	#111	#112	#113
Amino acids (FreAmine III)	MG	4.25%	2%	4.25%	2.125%
Amino acids (Travasol)	TR					4.25%
Fat emulsion 20%, intravenous (Intralipid)	KV			200 mL	125 mL
Dextrose		25%	25%	20%	25%	25%
Sodium		50 mEq	50 mEq	50 mEq	50 mEq	35 mEq
Potassium		40 mEq	40 mEq	40 mEq	40 mEq	30 mEq
Chloride		40 mEq	40 mEq	a	a	35 mEq
Phosphorus		13 mmol	13 mmol	6 mmol	6 mmol	15 mmol
Acetate		31 mEq	31 mEq	a	a	70.5 mEq
Calcium		16.7 mEq	16.7 mEq	10 mEq	10 mEq	4.7 mEq
Magnesium		10 mEq	10 mEq	5 mEq	5 mEq	5 mEq
Multivitamins		4 mL	4 mL	3.33 mL	3.33 mL
Trace elements		present	present	present	present	present
Heparin sodium		1000 units	1000 units	1000 units	1000 units
Sterile water		qs	qs	qs	qs

 

^a Both Intralipid (long-chain triglycerides) and MCT/LCT (medium- and long-chain triglycerides) tested.

		Concentration per Liter
Component		#114	#115	#116	#117	#118
Nitrogen (from amino acids)		7 g
Amino acids (Travasol)			4.2%	4.2%	4.5%	3.7%
Dextrose		12.5%	4.2%	21%	22.7%	18.5%
Fat emulsion, intravenous		50 ga				3.7%
Sodium		75 mEq	66.7 mmol	66.7 mmol	40.9 mEq	45 mEq
Potassium		60 mEq	50 mmol	50 mmol	36.4 mEq	40 mEq
Magnesium		15 mEq	4.16 mmol	4.16 mmol	7.3 mEq	8 mEq
Calcium		7.5 mEq	4.16 mmol	4.16 mmol	4.5 mEq	5 mEq
Chloride		75 mEq	66.7 mmol	66.7 mmol	48.2 mEq	53 mEq
Phosphorus		15 mmol	8.3 mmol	8.3 mmol	13.6 mmol	15 mmol
Sulfate		15 mEq
Acetate		45 mEq	90.8 mmol	90.8 mmol	76.4 mEq	84 mEq
Trace elements		present	present	present
Multivitamins		present	8.3 mL	8.3 mL
Sterile water for injection		qs
Iron			833 mcg	833 mcg
Heparin sodium			1000 units	1000 units

 

 

		Concentration per Liter
Component	Mfr	#119	#120	#121	#122	#123	#124	#125
Amino acids		4.25%	4.25%	5%	5%	1%	2%
Amino acids (TrophAmine)	MG							2%
Dextrose		35%	35%	20%	14.3%	10%	10%	10%
Fat emulsion					5.7%
Sodium chloride		50 mEq	50 mEq	20 mEq	4 mEq	16 mEq	16 mEq	16 mEq
Potassium chloride				20 mEq	30 mEq	5 mEq	5 mEq	5 mEq
Potassium phosphate		30 mEq	30 mEq		3 mmol	10 to 40 mmol	10 to 40 mmol	10 to 40 mmol
Magnesium sulfate		10 mEq	10 mEq	8 mEq	12 mEq	4 mEq	4 mEq	4 mEq
Calcium gluconate		4.7 mEq	4.7 mEq	4.8 mEq	4 mEq	10 to 40 mEq	10 to 40 mEq	10 to 40 mEq
Sodium phosphates				20 mEq
Sodium acetate					20 mEq	10 mEq	10 mEq	10 mEq
Cysteine HCl								1 g
Mixed electrolytes	LY				27 mL
Trace Elements		1 mL	1 mL	present	3 mL
Heparin sodium			1000 units
Multivitamins				10 mL	10 mL
Phytonadione					1 mg
Cimetidine HCl					1 g

 

 

		Concentration per Liter
Component	Mfr	#126	#127	#128	#129	#130	#131	#132	#133
Amino acids (Aminosyn II)	AB	2%	3.3%	3.6%	3.6%	5%	3.5%	3.5%
Amino acids (Travasol)	TR								4.25%
Dextrose		14.8%	3.3%	23.3%	20.8%	10%	25%	25%	25%
Fat emulsion, intravenous (Liposyn II)	AB	1.2%	3.3%	3.3%	2%	7.1%
Sodium		39.5 mEq	51.7 mEq	48.4 mEq	96.3 mEq	49.4 mEq	33.6 mEq	33.6 mEq	75 mEq
Potassium		27 mEq	13.3 mEq	21.4 mEq	60 mEq	78.6 mEq	35.6 mEq	35.6 mEq	20 mEq
Calcium		6.6 mEq	3 mEq	6.7 mEq	10 mEq	13.4 mEq	4.5 mEq	4.5 mEq	9.6 mEq
Magnesium		3.2 mEq	3.3 mEq	10 mEq	12 mEq	14.5 mEq	5 mEq	5 mEq	10 mEq
Phosphate		5.5 mmol	10 mmol	10 mmol	15 mmol	21.4 mmol	12 mmol	12 mmol	10 mEq
Chloride		57.9 mEq	23.3 mEq	40 mEq	80 mEq	73.9 mEq	35 mEq	35 mEq	85 mEq
Acetate		21.9 mEq	43.6 mEq	23.9 mEq	65.8 mEq	35.9 mEq	35.7 mEq	35.7 mEq
Trace elements		present	present	present	present	present		present	3 mL
Multivitamins (M.V.I.-12)								present	10 mL

 

 

		Concentration per Liter
Component	Mfr	#134	#135	#136	#137	#138	#139	#140
Amino acids (Travasol)		5.8%	5.8%	5.8%	5.8%	5.8%	4.26%	6%
Dextrose	BA	23.7%	23.7%	23.7%	23.7%	23.7%	17.5%	25%
Fat emulsion, intravenous (Intralipid)	KV		3%	5%			3%
Fat emulsion, intravenous (Liposyn II)	AB				3%	5%
Potassium chloride		54.2 mEq	54.2 mEq	54.2 mEq	54.2 mEq	54.2 mEq	40.2 mEq	30 mEq
Sodium chloride		108 mEq	108 mEq	108 mEq	108 mEq	108 mEq	80.5 mEq	110 mEq
Calcium gluconate 10%		13.6 mL	13.6 mL	13.6 mL	13.6 mL	13.6 mL	4.65 mEq	10 mL
Magnesium sulfate 50%		1.4 mL	1.4 mL	1.4 mL	1.4 mL	1.4 mL	4 mEq	4 mL
Potassium phosphate		20.3 mmol	20.3 mmol	20.3 mmol	20.3 mmol	20.3 mmol	45 mmol
Multivitamins		6.8 mL	6.8 mL	6.8 mL	6.8 mL	6.8 mL	5 mL	1 vial
Trace elements		present	present	present	present	present	present	present
Phytonadione								1 mg

 

 

		Concentration per Liter
Component	Mfr	#141	#142	#143	#144
Amino acids	AB		2.5%	5%
Amino acids (Travasol)	TR				4.25%
Dextrose		25%	25%	25%	25%
Sodium				50 mEq	22.5 mEq
Potassium			40 mEq	40 mEq	20 mEq
Magnesium			5 mEq	5 mEq	2.85 mEq
Calcium			5 mEq	5 mEq	4.25 mEq
Phosphorus			15 mmol	15 mmol	15.75 mmol
Chloride			58 mEq	58 mEq	17 mEq
Acetate					58 mEq
Multivitamins			10 mL	10 mL
Trace elements			1 mL	1 mL	present
Heparin sodium	UP		500 units	500 units
Sterile water for injection					qs

 

 

		Concentration per Liter
Component	Mfr	#145	#146	#147	#148
Amino acids (Travasol)	BA	5%
Amino acids	AB		5%	2.5%	1%
Dextrose		15%	25%	25%	25%
Sodium		45 mEq	35 mEq	35 mEq	35 mEq
Potassium		15 mEq	40 mEq	40 mEq	40 mEq
Chloride		20 mEq	35 mEq	35 mEq	35 mEq
Phosphorus		16 mmol	12 mmol	12 mmol	12 mmol
Acetate		81 mEq	82 mEq	82 mEq	82 mEq
Calcium		20 mEq	9 mEq	9 mEq	9 mEq
Magnesium			5 mEq	5 mEq	5 mEq

 

^a Intralipid 20%, Liposyn II 20%, and Nutrilipid 20% were each tested.

		Component Amounts
Component		#149	#150	#151	#152	#153	#154	#155	#156	#157	#158
Amino acids 10% (TrophAmine)		50 mL	50 mL	50 mL	50 mL	350 mL	350 mL	350 mL	350 mL	50 mL	350 mL
Dextrose		10%	10%	10%	10%	25%	25%	25%	25%	25%	25%
Fat emulsion 20%, intravenousa		25 mL	25 mL	70 mL	70 mL	25 mL	25 mL	70 mL	70 mL	100 mL	100 mL
Sodium		25 mEq	100 mEq	25 mEq	100 mEq	25 mEq	100 mEq	25 mEq	100 mEq	100 mEq	100 mEq
Potassium		15 mEq	80 mEq	15 mEq	80 mEq	15 mEq	80 mEq	15 mEq	80 mEq	80 mEq	80 mEq
Chloride		25 mEq	100 mEq	25 mEq	100 mEq	25 mEq	100 mEq	25 mEq	100 mEq	100 mEq	100 mEq
Calcium		7 mEq	18 mEq	7 mEq	18 mEq	7 mEq	18 mEq	7 mEq	18 mEq	18 mEq	18 mEq
Magnesium		2.5 mEq	13 mEq	2.5 mEq	13 mEq	2.5 mEq	13 mEq	2.5 mEq	13 mEq	13 mEq	13 mEq
Phosphate		3.4 mmol	9 mmol	3.4 mmol	9 mmol	3.4 mmol	9 mmol	3.4 mmol	9 mmol	9 mmol	9 mmol
Trace elements		present	present	present	present	present	present	present	present	present	present
Multivitamins (M.V.I. Pediatric)		5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL
Heparin		1000 units	1000 units	1000 units	1000 units	1000 units	1000 units	1000 units	1000 units	1000 units	1000 units

 

 

		Component Amounts
Component	Mfr	#159	#160	#161	#162	#163	#164	#165	#166
Amino acids 5.5% with electrolytes (Travasol)	BA	100 mL	100 mL	400 mL	400 mL	400 mL	400 mL	100 mL	100 mL
Fat emulsion 20%, intravenous (Intralipid)	KV	100 mL		200 mL		100 mL		200 mL
Fat emulsion 20%, intravenous (Liposyn II)	AB		100 mL		200 mL		100 mL		200 mL
Heparin sodium 1000 units/mL	ES	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL	5 mL
Dextrose 10%		795 mL	795 mL					695 mL	695 mL
Dextrose 20%				395 mL	395 mL	495 mL	495 mL

 

 

		Component Amounts
Component		#167	#168	#169	#170	#171	#172	#173
Aminoplex 12				500 mL		1000 mL
Aminoplex 24		500 mL	500 mL	500 mL	500 mL
Vamin glucose								1000 mL
Lipofundin S 20%		500 mL	500 mL	500 mL	500 mL	500 mL
Fat emulsion 10%, intravenous (Intralipid)							300 mL
Glucoplex 1000		1000 mL
Glucoplex 1600			1000 mL	1000 mL		500 mL
Dextrose 5%						1000 mL
Dextrose 50%					500 mL			1000 mL
Potassium chloride 15%			37.5 mL		10 mL
Potassium phosphate 17%		20 mL	20 mL	20 mL	20 mL	10 mL
Sodium chloride 30%			27 mL		15 mL
Addamel		10 mL	10 mL	10 mL	10 mL	10 mL		10 mL
Soluvit							7.5 mL
Vitalipid infant							15 mL
Pancebrin								10 mL

 

 

		Concentration per Liter
Component	Mfr	#174	#175	#176	#177	#178	#179
Amino acids	AB	25 g	50 g	15 g
Amino acids	TR				3%
Nitrogen						7.9 g	7 g
Dextrose		125 g	250 g	100 g	5%	100 g	125 g
Fat emulsion, intravenous (Intralipid)	KV					50 g	5 g
TPN II electrolytes	AB	20 mL	20 mL
Sodium		26.3 mEq	37.5 mEq	40 mEq	46 mEq	24 mmol	75 mEq
Potassium		35.5 mEq	40 mEq	50 mEq	40 mEq	12.5 mmol	60 mEq
Magnesium		5 mEq	5 mEq	10 mEq	8 mEq	2.5 mmol	15 mEq
Calcium		9 mEq	4.5 mEq	10 mEq	5 mEq		7.5 mEq
Phosphorus		12 mmol	45 mmol	5 mmol	12 mmol	4.5 mmol	15 mmol
Chloride		35 mEq	35 mEq	47.6 mEq	57 mEq	7 mmol	75 mEq
Acetate		25 mEq	43 mEq	31.8 mEq	61 mEq	40.5 mmol	45 mEq
Gluconate				10 mEq
Sulfate				10 mEq			15 mEq
Trace elements			present	present	present	present	present
Multivitamins (M.V.I. Pediatric)		3 mL		3 mL
Multivitamins (M.V.I. 9+3)			10 mL
Multivitamins					10 mL	present	present
Vitamin K			5 mg
Heparin sodium		1000 units	1000 units	1000 units	1000 units
Sterile water qs ad		1000 mL	1000 mL	1000 mL		1000 mL	1000 mL

 

 

		Component Amounts
Component		#180	#181
Amino acids 10%		1000 mL	400 mL
Dextrose 50%		500 mL	500 mL
Fat emulsion 20%, intravenous (Intralipid)		500 mL
Sodium		40 mmol	41 mEq
Potassium		70 mmol	22.7 mEq
Calcium		4.6 mmol	5 mEq
Magnesium		5 mmol	5 mEq
Phosphorus		17.5 mmol	12 mmol
Chloride		120 mmol	30 mEq
Acetate		45 mmol	89 mEq
Trace elements			present
Multivitamins			10 mL

 

 

		Concentration per Liter
Component	Mfr	#182
Amino acids	KV	5%
Dextrose		25%
Fat emulsion, intravenous (Intralipid)	KV	2.25%
Potassium phosphate		10 mmol
Potassium chloride		45 mEq
Sodium chloride		75 mEq
Magnesium sulfate		8 mEq
Calcium gluconate		47 mg
Trace elements		present
Multivitamins		5 mL
Sterile water qs ad		1000 mL

 

^a Neonatal formula.
^b Pediatric formula.
^c Adult formula.

		Component Amounts
Component	Mfr	#183	#184	#185	#186a	#187b	#188c	#189
Amino acids (Aminosyn II)	AB	1%	2.5%	5%
Amino acids (Aminosyn)	AB				15 g	25 g	50 g
Amino acids 10% with electrolytes								500 mL
(Synthamin 17 with electrolytes)
Dextrose	AB	10%	10%	25%	125 g	125 g	250 g
Dextrose 50%								500 mL
TPN II electrolytes						1 mL	1 mL
Calcium		9 mEq	4.4 mEq	5 mEq	1 mEq	9 mEq	4.5 mEq	2.2 mmol
Magnesium		5 mEq	5 mEq	5 mEq	1 mEq	5 mEq	5 mEq	2.5 mmol
Potassium		27 mEq	18 mEq	40 mEq	5 mEq	30 mEq	40 mEq	42.5 mmol
Sodium		24 mEq	38 mEq	42 mEq	4 mEq	35 mEq	37.65 mEq	45 mmol
Phosphorus		6 mmol	9 mmol	15 mmol	2 mmol	6 mmol	12 mmol	15 mmol
Chloride		35 mEq	35 mEq	43 mEq	5.7 mEq	46.9 mEq	39.4 mEq	55.65 mmol
Acetate		22 mEq	25 mEq	38 mEq	11.1 mEq	25.6 mEq	43.5 mEq	81.25 mmol
Gluconate					1.1 mEq	2.5 mEq	0.05 mEq
Sulfate					1.1 mEq
Trace elements		1 mL	1 mL	1 mL	0.6 mL	1 mL	1 mL	present
Multivitamins (M.V.I. Pediatric)	AST				3 mL	3 mL
Multivitamins (M.V.I. 9+3)	AST						10 mL
Heparin sodium	ES				1000 units	1000 units	1000 units
Sterile water					qs	qs	qs

 

 

		Component Amounts
Component	Mfr	#190	#191	#192
Amino acids (Aminosyn II 15%)	AB	333 mL
Amino acids (Azonutril 25)			500 mL
Amino acids				17 g
Dextrose 70%		500 mL
Dextrose 50%			250 mL
Dextrose 30%			750 mL
Dextrose				42.4 g
Fat emulsion 20%, intravenous (Intralipid)			500 mL	24.2 g
Fat emulsion 20%, intravenous (Liposyn II)	AB	400 mL
Sterile water		133 mL
Sodium				55.7 mmol
Potassium				19.4 mmol
Magnesium				2.3 mmol
Calcium				1.5 to 150 mmol
Phosphate				21 to 300 mmol
Unspecified electrolytes		present
Vitamins		present		present
Trace elements			present	present

 

 

		Component Amounts
Component	Mfr	#193
Amino acids 10%	CL	1000 mL
Dextrose 50%	CL	750 mL
Sodium chloride	AB	140 mEq
Potassium phosphates	AB	20 mmol
Calcium gluconate		4.8 mEq
Magnesium sulfate		40 mEq
Multivitamins	AST	10 mL
Trace elements	LY	3 mL
Famotidine		40 mg

 

 

		Concentration per Liter
Component		#194	#195
Amino acids		2.2%	2.2%
Dextrose		12.5%	20%
Sodium chloride		26 mEq	26 mEq
Potassium phosphates		15 mmol	15 mmol
Calcium gluconate		25 mEq	25 mEq
Magnesium sulfate		8 mEq	8 mEq
Potassium chloride		2 mEq	2 mEq
Heparin sodium		1000 units	1000 units
Cysteine		660 mg	660 mg
Trace elements		present	present
Multivitamins		20 mL	20 mL

 

 

		Concentration per Liter
Component	Mfr	#196	#197	#198	#199	#200
Amino acids	BA	6%	6%	6%	6%	6%
Dextrose	BA	24%	24%	24%	24%	24%
Intralipid	KV		3%	5%
Liposyn II	AB				3%	5%
Sodium chloride	LY	108 mEq	108 mEq	108 mEq	108 mEq	108 mEq
Potassium phosphates	AB	20 mmol	20 mmol	20 mmol	20 mmol	20 mmol
Calcium gluconate	LY	6.3 mEq	6.3 mEq	6.3 mEq	6.3 mEq	6.3 mEq
Magnesium sulfate	AST	5.6 mEq	5.6 mEq	5.6 mEq	5.6 mEq	5.6 mEq
Potassium chloride	AB	54 mEq	54 mEq	54 mEq	54 mEq	54 mEq
Trace elements	SO	present	present	present	present	present
Multivitamins	AR	6.8 mL	6.8 mL	6.8 mL	6.8 mL	6.8 mL

 

^a Calculated quantities from a pediatric peripheral line formula.
^b Calculated quantities from a pediatric central line formula.
^c Unspecified.

		Concentration per Liter
Component	Mfr	#201	#202	#203a	#204b
Amino acids	BA	4.25%
Amino acids	AB		4.25%
Amino acids (TrophAmine)	MG			2%	3%
Dextrose		25%	25%	10%	20%
Sodium		35 mEq	35 mEq	38 mEq	77 mEq
Potassium		30 mEq	30 mEq	20 mEq	40 mEq
Calcium		5 mEq	9.4 mEq	600 mg	600 mg
Magnesium		3 mEq	10 mEq	2.5 mEq	2.5 mEq
Chloride		47 mEq	c	38 mEq	77 mEq
Phosphate		14.3 mEq	15 mmol	400 mg	400 mg
Acetate		67 mEq	50 mEq	29 mEq	58 mEq
l-Cysteine				200 mg	300 mg
Trace elements			present	present	present
Multivitamins			present	present	present
Heparin					500 units

 

 

		Concentration per Liter
Component	Mfr	#205	#206
Amino acids	BA	5%
Aminosyn	AB		2.125%
Dextrose		25%	20%
Intralipid	KA
Liposyn II	AB
Sodium chloride		75 mEq	30 mEq
Potassium chloride		60 mEq	30 mEq
Potassium phosphates		20 mmol
Sodium phosphates			15 mmol
Calcium gluconate		10 mEq	14 mEq
Magnesium sulfate		10 mEq	50 mg
Trace elements		present	present
Multivitamins
Heparin sodium		3000 to 20,000 units

 

^a Tested with and without trace elements (Neotrace, Fujisawa).
^b Tested with and without multivitamins (M.V.I. Pediatric, Astra) 3.5 mL/L.
^c 40 mg/g of protein.

		Concentration per Liter
Component	Mfr	#207	#208	#209	#210	#211
Amino acids (TrophAmine)	MG	0.5%	1%	1.5%	2%	2.5%
Dextrose		10%	10%	10%	10%	10%
Sodium chloride		20 mEq	20 mEq	20 mEq	20 mEq	20 mEq
Sodium acetate		10 mEq	10 mEq	10 mEq	10 mEq	10 mEq
Potassium acetate		5 mEq	5 mEq	5 mEq	5 mEq	5 mEq
Potassium phosphates		10 mmol	10 mmol	10 mmol	10 mmol	10 mmol
Calcium gluconate		20 mEq	20 mEq	20 mEq	20 mEq	20 mEq
Magnesium sulfate		4 mEq	4 mEq	4 mEq	4 mEq	4 mEq
Trace elements	FUJ	a	a	a	a	a
Multivitamins	AST	b	b	b	b	b
Heparin sodium		1000 units	1000 units	1000 units	1000 units	1000 units
l-Cysteinec		200 mg	400 mg	600 mg	800 mg	1 g

 

^a Forty parenteral nutrition formulations within the ranges cited were tested. Specific formulations were not reported.
^b No phosphates added. Phosphates from FreAmine III formulation yielded 3.5 mmol/L.
^c Added phosphates indicated. All phosphates from addition plus FreAmine III formulation totaled 10 mmol/L.
^d Reported as potassium concentration.

		Concentration per Liter
Component	Mfr	#212	#213	#214	#215	#216a
Amino acids (Aminosyn II)	AB	3.5%		4.25%
Amino acids (FreAmine III)	MG		3.5%		4.25%
Amino acids (Travasol)	BA					0.5 to 5%
Dextrose		5%	5%	25%	25%	10 to 20%
Sterile water for injection		516.8 mL	516.75 mL	161 mL	158.6 mL	q.s.
Potassium phosphates		3.5 mmol	b	15 mmol	5.75 mmolc	0 to 20 mEq Kd
Sodium chloride		25 mEq	37.5 mEq	25 mEq	40 mEq	0 to 44 mEq
Sodium acetate						0 to 40 mEq
Potassium chloride		35 mEq	40 mEq	18 mEq	25 mEq	0 to 20 mEq
Magnesium sulfate		8 mEq	8 mEq	8 mEq	8 mEq	4 mEq
Calcium gluconate		9.3 mEq	5 mEq	9.15 mEq	7.5 mEq	19.2 to 28.8 mEq
Multivitamins	AST	10 mL	10 mL	10 mL	10 mL	14 mL
Trace elements		present	present	present	present	present
Heparin sodium	ES					500 units
Ranitidine (as HCl)	GL					0 to 84 mg

 

 

		Concentration per Liter
Component	Mfr	#217	#218	#219	#220
Amino acids		5%
Amino acids	MG		3%	3%
Amino acids	AB				3%
Dextrose		25%	5%	5%	5%
Intralipid	KA		2%
Liposyn II	AB			2%
Liposyn III	AB				2%
Sodium		50 mEq	43 mEq	43 mEq	41.6 mEq
Potassium		40 mEq	40 mEq	40 mEq	40 mEq
Chloride		58 mEq	45 mEq	45 mEq	35 mEq
Phosphorus		15 mmol	7.5 mmol	7.5 mmol	15 mmol
Calcium		5 mEq	5 mEq	5 mEq	9.15 mEq
Magnesium		8 mEq	8 mEq	8 mEq	8 mEq
Acetate			51.7 mEq	51.7 mEq	42 mEq
Heparin sodium		1000 units
Multivitamins		10 mL	10 mL	10 mL	10 mL
Phytonadione		1 mg
Trace elements		2 mL	1 mL	1 mL	1 mL
Sterile water for injection			qs	qs	qs

 

 

		Concentration per Liter
Component	Mfr	#221	#222	#223	#224	#225	#226
Amino acids	MG	4.9%	4.9%			6%	6%
Amino acids	AB			4.9%	6%
Dextrose		20%	20%	20%	11%	10.7%	10.7%
Intralipid	KA		3.5%				4%
Liposyn II	AB	3.5%				4%
Liposyn III	AB			3.5%	4%
Sodium		39.8 mEq	39.8 mEq	39.7 mEq	45 mEq	45 mEq	45 mEq
Potassium		40 mEq	40 mEq	40 mEq	40 mEq	40.2 mEq	40.2 mEq
Calcium		7.5 mEq	7.5 mEq	9.15 mEq	9.15 mEq	7.5 mEq	7.5 mEq
Magnesium		8 mEq	8 mEq	8 mEq	8 mEq	8 mEq	8 mEq
Chloride		45 mEq	45 mEq	35 mEq	35 mEq	51 mEq	51 mEq
Acetate		67.7 mEq	67.7 mEq	45 mEq	53.2 mEq	78.4 mEq	78.4 mEq
Phosphate		10 mmol	10 mmol	15 mmol	15 mmol	10 mmol	10 mmol
Multivitamins		10 mL	10 mL	10 mL	10 mL	10 mL	10 mL
Trace elements		1 mL	1 mL	1 mL	1 mL	1 mL	1 mL

 

 

		Concentration per Liter
Component	Mfr	#227	#228	#229	#230	#231
Aminosyn II	AB	2%	3.5%	4.25%	4.25%	5%
Dextrose	AB	10%	10%	15%	25%	25%
Sodium (as chloride)	AB	40 mEq	40 mEq	70 mEq	70 mEq	70 mEq
Potassium (as chloride)	AB	20 mEq	20 mEq	50 mEq	50 mEq	50 mEq
Magnesium (as sulfate)	AB	8 mEq	8 mEq	12 mEq	12 mEq	12 mEq
Phosphates (as potassium)	AB	up to 40 mmol	up to 40 mmol	up to 40 mmol	up to 40 mmol	up to 40 mmol
Calcium (as acetate)	AB	up to 40 mEq	up to 40 mEq	up to 40 mEq	up to 40 mEq	up to 40 mEq

 

 

		Component Amounts
Component	Mfr	#232	#233	#234	#235	#236	#237
Synthamin 17		500 mL	500 mL	500 mL	500 mL
Vaminolact	FRE					150 mL	150 mL
Dextrose 50%		500 mL	500 mL	500 mL	500 mL	180 mL	154 mL
Sterile water for injection		500 mL	500 mL	500 mL	500 mL
Intralipid 20%		500 mL	500 mL	500 mL	500 mL
Medialipide	BRN						50 mL
Albumin, human		100 mL	100 mL	200 mL	200 mL
Sodium chloride 10%						6.08 mL	6.08 mL
Potassium chloride 10%						18.66 mL	18.66 mL
Calcium chloride			7 mmol		7 mmol
Calcium gluconate/glucoheptonate						16.1 mL	16.1 mL
Magnesium sulfate			10 mmol		10 mmol
Magnesium sulfate 15%						1.64 mL	1.64 mL
Phosphorus (Phocytan)						14.56 mL	14.56 mL
Vitamins (Soluvit)						5 mL	5 mL
Trace elements, pediatric (OEP)						10 mL	10 mL

 

 

		Component Amounts
Component	Mfr	#238	#239	#240
Aminoplex 12	GEI	200 mL
FreAmine III	FRE		200 mL
Vamin 14	PH			200 mL
Dextrose 20%	BA	300 mL	300 mL	300 mL
Addiphos	PH	4 mL	4 mL	4 mL
Additrace	PH	2 mL	2 mL	2 mL

 

 

		Concentration per Liter
Component	Mfr	#241	#242
Aminosyn	AB	4.25%	5%
Dextrose		25%	25%
Calcium		4.5 mEq	4.5 mEq
Magnesium		5 mEq	5 mEq
Potassium		40 mEq	40 mEq
Sodium		35 mEq	35 mEq
Acetate		74.5 mEq	74.5 mEq
Chloride		52.5 mEq	52.5 mEq
Phosphorus		12 mmol	12 mmol
Heparin sodium		1000 units	1000 units

 

 

		Concentration per Liter
Component		#243	#244	#245
Amino acids (Aminosyn)		4%
Amino acids (TrophAmine)			3%
Nitrogen				0.8%
Dextrose		20%	20%	12.5%
Fat emulsion				5%
Sodium chloride		93 mEq	48 mEq	20 mEq
Potassium (from acetate and phosphate)		60 mEq	40 mEq	35 mEq
Calcium (as gluconate)		330 mg	600 mg	4.6 mEq
Chloride				60 mEq
Acetate				22.5 mEq
Magnesium sulfate		8 mEq	4.3 mEq	5 mEq
Trace elements (pediatric)		3 mL	3 mL
l-Cysteine HCl (40 mg/g amino acids)			1.2 g
Multivitamin injection (M.V.I. Pediatric)		5 mL	5 mL	present
Heparin sodium		500 units	500 units

 

^a Provided potassium 20 mEq and phosphate 10 mmol.

		Concentration per Liter
Component		#246	#247
Amino acids (Aminoplasmal L10)		1000 mL	1000 mL
Dextrose 37.5% with electrolytes		500 mL	500 mL
Dextrose 10%		500 mL	500 mL
Fat emulsion (Lipofundin-S 20%)		500 mL
Sterile water for injection			500 mL
Calcium gluconate		2.5 mmol	2.5 mmol
Magnesium sulfate		2 mmol	2 mmol
Addamel		10 mL	10 mL
Potassium phosphate		20 mLa	20 mLa
Sodium chloride 30%		8 mL	8 mL
Folic acid		15 mg	15 mg
Multivitamins		present	present
Trace elements		present	present

 

 

		Concentration per Liter
Component		#248	#249
Amino acids (Aminotripa 2)		3.3%
Amino Acids (Unicaliq N)			3%
Dextrose		19.4%	17.5%
Sodium		38.9 mEq	40 mEq
Potassium		30 mEq	27 mEq
Magnesium		5.6 mEq	6 mEq
Calcium		5.6 mEq	6 mEq
Chloride		38.9 mEq	59 mEq
Sulfate		5.6 mEq
Acetate		60 mEq	10 mEq
Gluconate		5.6 mEq	6 mEq
Citrate		12.2 mEq
l-Malate			17 mEq
l-Lactate			35 mEq
Phosphorus		206.7 mg	250 mg
Zinc		11.1 mcmol	20 mcmol

 

 

		Concentration per Liter
Component		#250	#251	#252	#253	#254	#255	#256	#257
Aminosyn II		4%	4%	3.7%	3.7%	2.8%	2.8%	2.5%	2.5%
Dextrose		17.6%	17.6%	16.1%	16.1%	17.6%	17.6%	16.1%	16.1%
Liposyn II		6.0%		5.5%		6.0%		5.5%
Intralipid			6.0%		5.5%		6.0%		5.5%
Sodium chloride				104 mEq	104 mEq			109 mEq	109 mEq
Potassium chloride				47 mEq	47 mEq			47 mEq	47 mEq
Potassium acetate				43 mEq	43 mEq			43 mEq	43 mEq
Sodium phosphates				11 mmol	11 mmol			11 mmol	11 mmol
Magnesium sulfate				6 mEq	6 mEq			6 mEq	6 mEq
Calcium gluconate				5.1 mEq	5.1 mEq			5 mEq	5 mEq
Sterile water for injection		qs	qs	qs	qs	qs	qs	qs	qs

 

 

		Concentration per Liter
Component		#258	#259	#260	#261	#262
FreAmine III		1%	2%	3%	4%	5%
Dextrose		15%	15%	25%	25%	25%
Cysteine HCl		250 mg	500 mg	750 mg	1 g	1.25 g
Sodium chloride		40 mEq	40 mEq	40 mEq	70 mEq	70 mEq
Potassium chloride		20 mEq	20 mEq	20 mEq	50 mEq	50 mEq
Magnesium sulfate		8 mEq	8 mEq	8 mEq	12 mEq	12 mEq
Sterile water for injection		qs	qs	qs	qs	qs

 

 

		Concentration per Liter
Component		#263	#264	#265	#266	#267
Travasol 10%		267 mL
Fravasol 10%			250 mL
Livaframine 10%				250 mL
Synthamin 10%					500 mL
Amino acids 17%						1000 mL
Dextrose 70%		347 mL
Dextrose 50%					500 mL	500 mL
Dextrose 10%			250 mL	250 mL
Sterile water for injection		367 mL
Fat emulsion 20%						500 mL
Sodium		36.6 mEq		5 mmoL
Potassium		26.6 mEq
Calcium		5 mEq
Chloride		50 mEq	20 mmoL	4.5 mmoL
Acetate			41 mmoL	31 mmoL
Phosphate		9 mmoL		5 mmoL
Trace elements		present

 

 

	Concentration per Liter
Component	#268
Aminosyn 15%	29.75 mL
Dextrose 70%	37.5 mL
Sterile water for injection	33.65 mL
Sodium chloride	4.7 mEq
Potassium chloride	2.1 mEq
Potassium phosphates	1.05 mmol
Magnesium sulfate	80 mg
Calcium gluconate	137 mg

 

 

		Concentration per Liter
Component		#269	#270	#271	#272	#273
Amino acids (Aminoplasmal 16%)		7.12%	7.34%	7.49%	7.6%	7.68%
Dextrose 70%		19.69%	20.35%	20.82%	21.0%	21.32%
Fat emulsion 20% (Lipofundin MCT)		2.49%	2.54%	2.58%	2.68%	2.69%
Sodium		118.6 mEq	97.8 mEq	83.3 mEq	72.4 mEq	64 mEq
Potassium		71.2 mEq	58.7 mEq	49.9 mEq	43.5 mEq	38.4 mEq
Calcium		11.9 mEq	9.8 mEq	8.3 mEq	7.2 mEq	6.4 mEq
Magnesium		11.9 mEq	9.8 mEq	8.3 mEq	7.2 mEq	6.4 mEq
Phosphate		28.5 mmol	23.5 mmol	19.9 mmol	17.4 mmol	15.4 mmol
Chloride		118.6 mEq	97.8 mEq	83.3 mmol	72.4 mEq	64.0 mEq
Trace elements		3.6 mL	2.9 mL	2.5 mL	2.2 mL	1.9 mL
Multivitamins		11.9 mL	9.8 mL	8.3 mL	7.2 mL	6.4 mL

 

 

		Concentration per Liter
Component		#274	#275
TrophAmine		3.75%
Amino acids			3.6%
Dextrose		17.5%	10.6%
Sodium		25 mEq	36 mEq
Potassium		19 mEq	25.5 mEq
Calcium		19 mEq	6.4 mEq
Magnesium		3.8 mEq	6.4 mEq
Phosphates		12.5 mEq	5.5 mmol
Acetate		25 mEq	70 mEq
M.V.I.-Pediatric		52 mL
Trace elements (pediatric)		2.5 mL
Ranitidine HCl		73 mL

 

 

	Concentration per Liter
Component	#276
Aminosyn	4.25%
Dextrose	25%
Sterile water for injection	97.68 mL
Sodium chloride	50 mEq
Potassium chloride	40 mEq
Potassium phosphates	10 mmol
Magnesium sulfate	8 mEq
Calcium chloride and gluconate	10 mEq

 

^a Trace elements: chromium, copper, iron, manganese, iodine, fluorine, molybdenum, selenium, and zinc.

		Component Amounts
Component	Mfr	#277	#278
Amino acids (Neonutrin 15%)	FRK	500 mL	500 mL
Dextrose 40% (Ardeanutrisol)	ARD	500 mL	500 mL
Fat emulsion 20% (Smoflipid)	FRK	250 mL
Fat emulsion 20% (Lipoplus)	BRN		250 mL
Sodium chloride 10%	ARD	10 mL	10 mL
Potassium chloride 7.45%	ARD	10 mL	10 mL
Calcium gluconate 10%	HB	10–40 mL	10–40 mL
Magnesium sulfate 10%	HB	10–40 mL	10–40 mL
Potassium phosphate 13.6%		10–40 mL	10–40 mL
Trace elements (Addamel N)	FRK	10 mL	10 mL

 

^a Available as a 3-chamber bag of NuTRIflex Lipid Special (Braun) in a fixed volume and concentration with no additional additives.
^b Available as a 3-chamber bag of NuTRIflex Omega Special (Braun) in a fixed volume and concentration with no additional additives.

	Component Amounts
Component	#279a	#280b
Amino acids 14%	250 mL
Amino acids 14.36%		250 mL
Dextrose 39.6%	250 mL	250 mL
Fat emulsion 20%	125 mL	125 mL
Sodium	33.5 mmol	33.5 mmol
Potassium	23.5 mmol	23.5 mmol
Magnesium	2.65 mmol	2.65 mmol
Calcium	2.65 mmol	2.65 mmol
Zinc	0.02 mmol	0.02 mmol
Chloride	30 mmol	30 mmol
Acetate	30 mmol	30 mmol
Phosphate	10 mmol	10 mmol

ASHP® Handbook on Injectable Drugs®. © Copyright, 1977-2020. American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Original Publication Date: October 1, 2006. Selected Revisions: September 30, 2019. Database Extraction: 02/05/2020 15:45:21 -0500+